These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1173 related articles for article (PubMed ID: 23328268)
1. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268 [TBL] [Abstract][Full Text] [Related]
2. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478 [TBL] [Abstract][Full Text] [Related]
3. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. Lee S; Lee HY; Park KW; Kang HJ; Koo BK; Kim HS; Choi DJ; Kim MA; Oh BH Am J Cardiovasc Drugs; 2013 Dec; 13(6):413-24. PubMed ID: 23913405 [TBL] [Abstract][Full Text] [Related]
4. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860 [TBL] [Abstract][Full Text] [Related]
5. Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial. Kim SH; Sung JH; Shin J; Lee HJ; Lee HS; Cho DK; Lim SW Curr Med Res Opin; 2015 Mar; 31(3):449-57. PubMed ID: 25586295 [TBL] [Abstract][Full Text] [Related]
6. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA; Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518 [TBL] [Abstract][Full Text] [Related]
9. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389 [TBL] [Abstract][Full Text] [Related]
10. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250 [TBL] [Abstract][Full Text] [Related]
11. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493 [TBL] [Abstract][Full Text] [Related]
12. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
13. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751 [TBL] [Abstract][Full Text] [Related]
14. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
15. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259 [TBL] [Abstract][Full Text] [Related]
17. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152 [TBL] [Abstract][Full Text] [Related]
19. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669 [TBL] [Abstract][Full Text] [Related]
20. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]